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Abstract
Objective: Long-term oxygen therapy (LTOT) during 15 h/day or more prolongs survival in patients with chronic
obstructive pulmonary disease (COPD) and severe hypoxemia. No randomized controlled trial has evaluated the net
effects (benefits or harms) from LTOT 24 h/day compared with 15 h/day or the effect in conditions other than COPD.
We describe a multicenter, national, phase IV, non-superiority, registry-based, randomized controlled trial (R-RCT) of
LTOT prescribed 24 h/day compared with 15 h/day. The primary endpoint is all-cause-mortality at 1 year. Secondary
endpoints include cause-specific mortality, hospitalizations, health-related quality of life, symptoms, and outcomes in
interstitial lung disease.
Methods/design: Patients qualifying for LTOT are randomized to LTOT 24 h/day versus 15 h/day during 12months
using the Swedish Register for Respiratory Failure (Swedevox). Planned sample size in this pragmatic study is 2126
randomized patients. Clinical follow-up and concurrent treatments are according to routine clinical practice. Mortality,
hospitalizations, and incident diseases are assessed using national Swedish registries with expected complete follow-
up. Patient-reported outcomes are assessed using postal questionnaire at 3 and 12months.
Discussion: The R-RCT approach combines the advantages of a prospective randomized trial and large clinical national
registries for enrollment, allocation, and data collection, with the aim of improving the evidence-based use of LTOT.
Trial registration: Clinical Trial registered with www.clinicaltrials.gov, Title: REgistry-based Treatment Duration and
Mortality in Long-term OXygen Therapy (REDOX); ID: NCT03441204.
Keywords: Register-based randomized controlled trial, Hypoxaemia, Long-term oxygen therapy, Oxygen duration,
Chronic obstructive pulmonary disease, Interstitial lung disease, Mortality, Hospitalizations, Health-related quality of life,
Symptoms
Background
Long-Term Oxygen Therapy (LTOT) is an established
treatment to improve survival in patients with chronic
daytime hypoxemia due to chronic obstructive pulmonary
disease (COPD) [1]. Internationally accepted guidelines
recommending that LTOT should be given for 15 h/day or
more [2] are based on two small randomized controlled
trials (RCTs) conducted in the 1970s with a total of 290
patients; the ‘Continuous or Nocturnal Oxygen Therapy’
trial (NOTT) published in 1980 [3] and the ‘Medical
Research Council’ (MRC) study published in 1981 [4]. In
NOTT, prescribed oxygen duration 24 h/day (mean use
18 h/day) increased survival compared with 12 h/day, and
in the MRC study oxygen 15 h/day increased survival
compared with no oxygen. The internationally accepted
recommendation to use LTOT at least 15 h/day and pref-
erably 24 h/day is based on an unadjusted observational
comparison of the treatment arms of these two trials,
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where the crude mortality rate was lower for the 18 h/day
group in NOTT than for the 15 h/day group in the MRC
trial [5] (21% vs 41%). However, the presumed survival
benefit of continuous LTOT over 15 h /day has not been
proven in a randomized controlled trial. Our recently per-
formed observational study of 2249 patients using LTOT
for hypoxemic COPD suggested that there may indeed be
no differences in survival for LTOT 24 h/day compared
with 15 h/day [6]. As for LTOT to patients with mild hy-
poxemia at rest or with isolated hypoxemia during exer-
tion, the recent ‘Long Term Oxygen Therapy’ (LOTT)
trial showed no reduced mortality [7], and a Cochrane
metaanalysis reported some effect on breathlessness but
not on health related quality of life (HRQoL) [8].
LTOT is associated with considerable logistic chal-
lenges, costs and side effects [9, 10]. Being connected to
oxygen equipment is associated with feelings of shame,
restrictions of daily activities, and social isolation [11,
12]. Thus, continuous LTOT may pose an unnecessary
burden and limitation for many patients compared with
treatment 15 h/day, where they can be free of their oxy-
gen for 9 h/day. The longer the duration of daily therapy,
the less likelihood of adherence to treatment. Low-flow
oxygen therapy has been associated with oxidative stress
and inflammation [13], which could potentially contrib-
ute to increased morbidity and negative health effects
[14, 15]. Moreover, the validity of the NOTT and MRC
trials for current practice is questionable as the studies
included mainly men and people younger than 70 years
without significant comorbidity. Of note, treatment for
COPD and cardiovascular disease has also improved in
recent decades [5, 9]. The results of the NOTT and
MRC trials are also generally applied for all conditions
with secondary hypoxemic respiratory failure, although
intervention studies of LTOT in pulmonary fibrosis,
heart failure and pulmonary hypertension are lacking.
Thus, improved evidence-based LTOT is needed.
The Registry-based randomized controlled trial (R-RCT)
is a recent scientific paradigm shift that can facilitate large
interventional trials with adequate power and low cost [16]
to detect clinically important patient outcomes pragmati-
cally in the real world setting [17]. The trial design was
pioneered by Swedish cardiologists in the TASTE study of
thrombus aspiration using the Swedish Coronary Angiog-
raphy and Angioplasty Registry, which enabled inclusion of
a large nationally representative sample, and the study was
highly cost-effective [16].
This paper presents the protocol for a Swedish national
multisite R-RCT; REgistry based randomized controlled
trial of treatment Duration and mortality in long-term
OXygen therapy (REDOX), to test the primary research
hypothesis that LTOT 24 h/day does not reduce all-cause
mortality compared with LTOT 15 h/day in patients with
oxygen-dependent COPD. Secondary outcomes include
cause-specific mortality, hospitalizations, health-related
quality of life, symptoms, effects in other underlying
diseases, and effects by the level of hypoxemia at baseline.
Methods/design
Objectives
The main aim is to determine whether oxygen prescribed
continuously 24 h/day changes all-cause-mortality rate at
1 year in a similar way as oxygen prescribed for 15 h/day
during long-term oxygen therapy (LTOT). Secondary out-
comes include mortality rate from all causes at 3 and 12
months, mortality rate from respiratory disease at 3 and
12months, mortality rate from cardiovascular disease at 3
and 12months, hospitalization rate from all causes at 3
and 12months, hospitalization rate with a primary diag-
nosis of respiratory disease or respiratory infection at 3
and 12months, hospitalization rate with a primary diag-
nosis of cardiovascular disease at 3 and 12months, rate of
an incident diagnosis of cardiovascular disease at 3 and
12months, self-rated oxygen utilization, breathlessness,
fatigue, informant-rated cognition, self-rated cognition,
health-related quality of life (HRQoL), global impression
of change from baseline, self-reported physical activity
and preference of continuing treatment. All key research
questions are bulleted in Table 1.
Design and participants
The REDOX is a multicenter, single-blinded (analyst), ef-
fectiveness, phase IV R-RCT. Current Swedish guidelines
recommend LTOT to be used for at least 15–16 h/day but
preferably 24 h/day [18]. In the present study, patients
starting LTOT will be randomized to either oxygen pre-
scribed 24 h/day or 15 h/day using the Swedish Register
for Respiratory Failure (Swedevox). Clinical follow-up and
concurrent treatments are according to routine clinical
practice. The main endpoints of mortality, hospitaliza-
tions, and incident disease are assessed using Swedish
registry data, with expected complete follow-up due to
compulsory registrations nationally. Patient-reported out-
comes are assessed using postal questionnaire at three and
12months. The study is managed by the Uppsala Clinical
Research Center (UCR), a clinical trial unit with great
experience from national randomized controlled trials. All
48 centers prescribing LTOT in the Swedish Quality
Register for Respiratory Failure (Swedevox) are invited to
participate in the trial. The study design is outlined in
Fig. 1. The inclusion and exclusion criteria for the trial are
listed in Table 2. As all patients eligible for starting LTOT
are included regardless of the underlying disease, the
overall study population is expected to be heterogeneous.
The main analysis will be in the defined group of patients
with spirometrically verified COPD and severe hypoxemia.
Secondary analyses will also be performed in sub popula-
tions listed in Table 3.
Sundh et al. BMC Pulmonary Medicine           (2019) 19:50 Page 2 of 8
Recruitment
All units prescribing and managing LTOT in Sweden
report to Swedevox registry, which has a nationwide
coverage of 85% of patients starting LTOT [18]. Ap-
proximately 70% of patients start LTOT due to COPD
and 15% due to interstitial lung disease (ILD) [3]. In
accordance with Swedish legislation and regulations,
patients starting LTOT are given written information
about Swedevox including the choice to opt-out from
registration in Swedevox or for their data to be re-
moved from the register at any time.
The oxygen staff at all units will be instructed to register
all patients eligible for LTOT in Swedevox, using the
standard online interface at the time of starting the oxygen
treatment, in accordance with current clinical routine.
The patients will be informed about the study verbally and
by written information, that taking part is entirely volun-
tary and that they can withdraw from study whenever they
want without this affecting their usual care. Written
informed consent will be obtained from all participants
before randomization. Participants will be eligible for in-
clusion up to 4 weeks after the start date of LTOT.
Before randomization, the patient’s Swedish identity
number; start date; and type of oxygen therapy (i.e. LTOT
and not palliative or ambulatory oxygen therapy) will be en-
tered in Swedevox. Eligible patients are identified and writ-
ten informed consents or reasons for non-participation will
be documented in a study specific module of the Swedevox
registry. To facilitate randomization, the Swedevox registry
will have a randomization list prepared by a study inde-
pendent statistician. Patients will be randomized in a 1:1 ra-
tio to be prescribed either LTOT 24 h/day or 15 h/day.
Swedevox will directly show which LTOT duration the pa-
tient should receive and the patient will be given standard-
ized written information about the allocated treatment. The
first study day is defined as the day of randomization. Pa-
tients can only enter the study once. The staff will inform
the patient and caregiver about the allocated daily oxygen
duration in the patient’s medical record (as part of routine
care) to facilitate subsequent follow-up of the oxygen use.
National guidelines recommend that ambulatory and active
patients are prescribed portable oxygen equipment to facili-
tate adherence to the prescribed daily oxygen duration [18].
This is a single-blinded (analyst) trial. The patient,
principal investigators and co-investigators, responsible
study nurses, study monitor, caregiver, and the clinical
oxygen staff will be aware of the allocated daily treat-
ment duration. The patient and caregiver will receive
standardized written information about the study and
the allocated LTOT duration. The patient and caregiver
will be instructed on the importance of using the LTOT
as prescribed and to inform the oxygen staff about any
changes in oxygen use which are documented in the pa-
tient’s medical record. The UCR study staff and statisti-
cian responsible for analyzing the study data will be
blinded to the allocated treatment group. The objective
primary endpoint of all-cause mortality in a single
blinded trial design is robust and minimizes the risk of
ascertainment and reporting bias [19].
Power and sample size
Based on Swedevox data which have been stable over
the last 5 years [18], the one year survival probability
with LTOT prescribed 15 h/day is 0.70. For superiority,
the survival probability should exceed 0.74 for LTOT 24
h/day. The clinical limit of superiority is thus an increase
in survival of 6%. With a non-superiority test for two
survival curves using a Cox proportional hazards model,
significance level 0.05, power 80%, balanced allocation,
the assumptions of a constant hazard ratio throughout
the study and complete follow-up of subjects, the esti-
mated sample size is 1063 patients. Allowing for that up
to 50% of patients in Swedevox may not be included in
the primary intention to treat (ITT) analysis set due to
non-COPD, or no verified severe hypoxemia (based on
current Swedevox data). The final planned total trial size
is 2126 randomized patients. Given that 1300 patients
start LTOT in Swedevox each year (which has been
stable over the last 5 years), of whom approximately 850
have COPD, and a rate of recruitment to the study of
75%, study recruitment is estimated to be completed
within 27 months.
Table 1 Key research questions addressed by this study
protocol
Does LTOT prescribed for 24 h/day versus 15 h/day:
Primary:
• Fail to reduce mortality rate from all causes?
Secondary:
• Fail to reduce mortality rate from respiratory disease?
• Fail to reduce mortality rate from cardiovascular disease?
• Fail to reduce hospitalization rate from all causes?
• Fail to reduce hospitalization rate from respiratory disease?
• Fail to reduce hospitalization rate from cardiovascular disease?
• Fail to reduce the rate of an incident diagnosis of cardiovascular
disease?
• Fail to reduce the level of breathlessness?
• Fail to reduce fatigue?
• Fail to improve level of self-reported physical activity?
• Fail to improve health-related quality of life?
• Fail to improve cognition?
• Fail to decrease the rate of LTOT withdrawal?
• Fail to increase the patient’s preference in continuing LTOT?
Abbreviations: LTOT = Long-term oxygen therapy
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Measurements
The pre-specified endpoint measurements include
registry-based outcomes and questionnaire data, as pre-
sented in Table 4.
Registry-based outcome assessments
The main endpoints of mortality and hospitalizations
will be assessed using national Swedish governmental
registries: date and causes of death (Causes of Death
Register), and the date and diagnoses/procedural codes
of hospitalizations (National Patient Register of in- and
outpatient care) [20, 21]. Data will be cross-linked be-
tween registers using each participant’s unique Swedish
identity number. In addition, data will be obtained on
dispensed outpatient medications (Prescribed Drug
Register) [22]. Endpoints will be assessed at three
months and 12 months after randomization (study end).
The completeness of the outcome registers ensures min-
imal loss of data and unbiased analysis according to the
intention to treat principle.
Patient questionnaires
At 3months (range 2 to 5 months) and 12months
(range 10 to 14months) after randomization, all
non-deceased participants (according to the Population
Register) will be sent a letter marked by the patient’s
randomization number. This will be sent by the UCR
Registry Unit (separated from the Clinical Research Unit
responsible for managing of the study) and will include a
standardized reminder about the allocated treatment to
the patient and caregiver, a questionnaire including data
on smoking and secondary endpoints, and instructions
about how to fill out and return the questionnaires
within 2 weeks in a stamped return envelope. If the
questionnaire has not been returned to the UCR data
management unit within 3 weeks, a reminder letter will
be sent home to the patient. The questionnaire data will
be entered into a database as reported (missing and in-
complete data accepted) and quality checked by the
UCR data management unit.
The questionnaire data will include the Multidimen-
sional Dyspnea Profile (MDP) [23], the modified Medical
Fig. 1 Flow chart of the outline of the study. aRandomization at or within four weeks of starting LTOT. Abbreviations: LTOT = Long-term oxygen
therapy. COPD = Chronic Obstructive Pulmonary Disease
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Research Council (mMRC) breathlessness scale [24, 25],
the Functional Assessment of Chronic Illness Therapy
(FACIT)- fatigue scale [26], the Informant Questionnaire
on Cognitive Decline in the Elderly (IQCODE) [27], the
Brief Anosognosia Scale (BAS) [28], the Functional Ac-
tivities Questionnaire (FAQ) [29], the COPD Assessment
Test (CAT) [30], the Euro-QoL-5- dimensions-five levels
(EQ-5D-5L) [31] and the modified Grimby activity ques-
tionnaire [32]. In addition, the worst breathlessness in
the previous week will be self-rated on a numeric rating
scale from 0 (neutral) to 10 (excruciating), and refractory
breathlessness will be reported through answering yes to
the question “Do you have breathlessness at rest or with
minimal activity that is distressful? [33] The global im-
pression of dyspnea scale will be used to provide infor-
mation on the participant’s perception of their change in
dyspnea since the start of the study, on a 7-point scale.
Finally, the treatment reference of two allocation arms
will be reported. The time for completion of the ques-
tionnaire is expected to be maximum an hour.
Adverse events
Adverse events (AEs) will be collected at the patient’s or-
dinary clinical visits and documented. The investigators
Table 2 Inclusion and exclusion criteria
Inclusion Criteria
• Age 18 years or older
• Standard eligibility criteria for non-palliative LTOT at rest: [1, 2]
o PaO2 < 7.4 kPa or oxygen saturation < 88% breathing air, or
o PaO2 < 8.0 kPa on air and either signs of heart failure or
polycythemia (EVF > 0.54)
Exclusion Criteria
• Standard contraindications for LTOT
• Smoking or contact with open fire
• Other inability to safely comply with LTOT
• Already on LTOT for more than 4 weeks
• Inability to comply with any of the study interventions (LTOT 15 h
/day or 24 h/ day) as judged by the responsible oxygen staff
• Opt out from being registered in Swedevox
• Inability to give informed written consent to participate in the study
as judged by the responsible oxygen staff
• Lack of Swedish identification number
• Previous participation in the study
Abbreviations: LTOT Long-term oxygen therapy, PaO2 arterial blood gas
tension of oxygen, EVF Erythrocyte Volume Fraction
Table 3 Analysis populations
Primary analysis population:
I. Participants with verified COPD (FEV1/FVC < 0.7 after bronchodilation)
with severe resting hypoxemia (PaO2 < 7.4 kPa) when starting LTOT
Secondary analysis populations:
II. Participants with ILD as main reason for starting LTOT with severe
hypoxemia (PaO2 < 7.4 kPa breathing air) at LTOT start
III. Participants with moderate hypoxemia (PaO2 7.4–8.0 kPa on air) at
LTOT start by diagnosis and as a discrete group
IV. All participants
Abbreviations: COPD Chronic Obstructive Pulmonary Disease, FEV1 Forced
Expiratory Volume in one second, FVC Forced Expiratory Volume, PaO2 arterial
blood gas tension of oxygen, LTOT Long-term oxygen therapy, ILD interstitial
lung disease
Table 4 Study assessments




Height and weight X
Spirometry X
Blood gases on air and oxygen X
Primary and secondary causes
of starting LTOT
X
Oxygen dose, equipment and
duration
X
Use of long-term mechanical
ventilator
X X
Date and reason of LTOT
withdrawal
X X
Cause of Death Register





Hospitalizations X X X
Prescribed Drug Register
Dispensed drug prescription X X X
Clinical visits
Adverse events (X)a (X)a
Patient questionnaire
Self-reported oxygen utilization X X
Breathlessness (MDP, NRS of
worst, refractory, mMRC)
X X





(BAS, IQCODE and FAQ)
X X
HRQoL (EQ -5D-5 L and CAT) X X
Global impression of change X X
Treatment preference X X
aAdverse events will be collected at the patient’s ordinary clinical visits.
Abbreviations: LTOT long-term oxygen therapy, MDP Multidimensional
Dyspnea Profile, NRS numeric rating scale, mMRC modified Medical Research
Council, FACIT Functional Assessment of Chronic Illness Therapy, IQCODE
Informant Questionnaire on Cognitive Decline in the Elderly, BAS Brief
Anosognosia Scale FAQ Functional Activities Questionnaire, HRQoL Health
Related Quality of Life, CAT the COPD Assessment Test, EQ-5D-5 L = the
EuroQoL 5 dimensions - 5 levels
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will assess the intensity and causality of the AE. Known
side effects from oxygen treatment (e.g. nose and upper
airways dryness and congestion) will therefore not be
reported.
Events with the outcome death or hospitalization will
not be reported as AE. These are primary and secondary
endpoints which will be captured as registry data. For
the same reason, incident diagnosis of cardiovascular
disease will not be reported as AE.
Quality assurance and control plans
The trial will be monitored in accordance with the prin-
ciples of Good Clinical Practice (GCP). Both centralized
monitoring activities and on-site monitoring activities
will be used in this study. Based on a study design with
very few study specific procedures, it has been decided
that the major part of the monitoring will be performed
using centralized methods.
The monitor will review source documents for verifi-
cation of consistency with the study data base according
to risk based monitoring. Data on the primary endpoint
of mortality and of hospitalization will be complete due
to follow-up using national registries. In terms of review
of completed informed consent, a random sample of the
patients will be checked by the monitor in connection
with on-site visit. Sites will also log all completed in-
formed consents and fax this log to the monitor on an
on-going basis. The monitor will review the log to verify
consistency with the study data base. If it is indicated
that the site does not comply with the specified consent
process, extended site-specific training and/or increased
monitoring activities will be performed.
Data management plan
The data management work will be performed by UCR.
The Data Management Plan (DMP) describes the data
flow within the study. A study database with all included
patients will be generated, and the study specific
randomization module and study specific variables from
separate pCRFs (=Patient Questionnaire) will be entered
into an Electronic Data Capture (EDC) system. Quality
control procedures will apply and be described in the
DMP, e.g. for entry of the patient questionnaires. All
data will be merged at study end and exported to an
analysis database for further analysis.
Analysis plan
The primary analysis will be according to the intention
to treat (ITT) principle and complemented with a per
protocol (PP) analysis, as non-compliance to the allo-
cated treatment may cause a potential bias towards
equivalence between treatments. The primary endpoint
of mortality will be analyzed with Cox’s proportional
hazards model. Hospitalizations will be analyzed using
Fine Gray regression, accounting for death as a compet-
ing event. Other secondary endpoints will be analyzed
using two-sided Student’s t-tests for continuous variables
(including HrQoL, breathlessness, cognition, fatigue, and
activity scores, as well as health care usage) and chi-2
test for categorical variables (causes of death and pa-
tient’s preference of continuing LTOT). Correlational
analyses, including of factors predictive of the primary
and secondary outcomes, will be conducted using linear
regression (continuous outcomes), logistic regression
(categorical outcomes), and Cox and Fine-Gray regres-
sion models (time to event outcomes).
Ethics, consent and permissions
A steering committee including all coauthors of the
protocol paper are responsible for design, methodology
and protocol amendments of the study. The study will
be conducted in accordance with the protocol, applic-
able regulatory requirements such as, but not limited to,
LVFS 2011:19, Good Clinical Practice and the ethical
principles of the Declaration of Helsinki as adopted by
the 18th World Medical Assembly in Helsinki, Finland,
in 1964 and subsequent versions. The study (Protocol
version 1.5, dated 2016-09-13) is approved by the Ethical
Board of Lund, Sweden (DNr 2016/190) and by the
Swedish Medical Products Agency (DNr: 5.1–
2016-71,695). Recruitment started in May 2018.
Discussion
This is the first study to compare effectiveness of LTOT
duration of 24 and 15 h/day on clinical outcomes in
people with chronic respiratory failure, with a potential
direct impact on research and clinical management.
LTOT is used commonly as it is one of few interventions
that can affect prognosis in COPD, but there has been
no trial of LTOT in severe hypoxemia since the 1970s
[3, 4]. Research in LTOT has been held back by prob-
lems and high cost of recruitment and follow-up of pa-
tients with advanced disease, and challenges with ethical
justification to withhold oxygen 24 h/day in patients with
severe hypoxemia for the purpose of conducting a clin-
ical trial even though there is no clear evidence of diffe-
rence in outcomes between shorter and longer duration
LTOT. This study will be by far the largest study in
LTOT to date, and the first R-RCT in respiratory medi-
cine. The R-RCT design is a paradigm shift and enables
a large-scale, randomized trial in a representative sample
of people with very advanced disease, with complete
follow-up of main endpoints. This will be the first trial
investigating whether LTOT 24 h/day improves im-
portant patient outcomes − survival time, risk of
hospitalization, levels of symptoms, oxygen side effects,
and HrQoL compared with LTOT 15 h/day, or whether
LTOT 24 h/day might unnecessarily constraint and
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burden patients. This study will also for the first time
evaluate effects of LTOT by the degree of hypoxaemia
and in people with disease other than COPD. Further,
evaluating the effect on the risk of hospitalization is cru-
cial as hospitalization is a major driver of health care
costs [34]. If COPD hospitalizations can be reduced by
LTOT 24 h/day compared with 15 h/day, increased use
of long term oxygen treatment could be cost-effective,
which will be evaluated in a comprehensive health eco-
nomic analysis. The trial will also examine the effect of
LTOT prescribed 24 h/day compared with 15 h/day on
survival and other outcomes, several of which were not
assessed in the LOTT trial of patients with moderate
hypoxemia [7]. The study will investigate effectiveness of
the prescription of LTOT in clinical care. No objective
measurement of oxygen use will be used, as there is no
accepted, user-friendly objective means of collecting
usage data. However self-reported actual oxygen dur-
ation will be collected.
If LTOT 24 h/day is found to be non-superior to 15 h/
day, this will confirm that patients safely can be free of
supplemental oxygen for up to nine hours per day. If
not, LTOT 24 h/day may be superior which implies the
importance of oxygen therapy in chronic respiratory fail-
ure and the relevance of implementing services to facili-
tate and optimize the daily duration of LTOT. The trial
design will provide robust, detailed data using validated
instruments that enable correlational analyses of factors
influencing the adherence to and net clinical effective-
ness of LTOT in patients with respiratory failure in
current clinical practice. The study also aims to take for-
ward an infrastructure for randomized trials that can be
used to facilitate research and improved evidence-based
treatment in patients with chronic respiratory failure.
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